Saracatinib synergizes with enzalutamide to downregulate androgen receptor activity in castration resistant prostate cancer
R. E. White, M. Bannister, A. Day, H. E. Bergom, V. M. Tan, J. Hwang, H. D. Nguyen, J. Drake
This study shows that combining saracatinib with enzalutamide reduces androgen receptor activity and DNA replication in CRPC cell lines, leading to increased apoptosis.
bioRxiv · Apr 22, 2023 · PreprintCancer Biology